Search

Displaying results 981 - 990 of 7062 in total
  1. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604]. … It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label].

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  2. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation. … [A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.

  3. Drug

    Tiapride

    go.drugbank.com/drugs/DB13025
    Investigational

    Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

    Categories: Dopamine D2 Receptor AntagonistsProducts: TIAPRID 1A PHARMA 200MG, TIAPRID 100 1A PHARMA
  4. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular … [L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER

  5. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. … HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine.

  6. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    [L7489] Atezolizumab was granted FDA approval on 18 October 2016. … [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.

  7. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [A32565]. … Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa).

  8. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    Midecamycin is a naturally occurring 16-membered macrolide [A33072] that fits under the category of acetoxy-substituted macrolide antibiotics.

    Synonyms: Espinomycin A
  9. Drug

    Chlordiazepoxide

    go.drugbank.com/drugs/DB00475
    ApprovedIllicit

    An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

    Mixtures: Limbitrol DS, AA PHARMA CHLORAX CAPSULE
  10. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death.